For in vivo assays, the development of PET ligands targeting A2BR and A3R has still been limited to receptor occupancy studies, biodistribution, or pharmacokinetic characterization, while PET ligands for A1R and A2AR have blossomed in clinical studies, particularly for neurological disorders. Here, ADORA2A is linked to nervous system disorder.